	Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis. JAMA Oncol Miszczyk M, Mastroleo F, Kujawska A, Gurwin A, Marvaso G, Kói T, Calleris G, Rasing M, Chin J, Fuller D, Nathan A, Peters M, van der Voort van Zyp J, Jenjitranant P, Hruby G, Soeterik TFW, Francolini G, Exterkate L, Overduin CG, Marra G, Gontero P, Alfarhan AR, Rajwa P, Kishan AU, Jereczek-Fossa BA, Shariat SF, DEFER-PC Collaborators. PMID: 42060279 [PubMed - as supplied by publisher]
	Management of lower urinary tract symptoms before prostate cancer radiotherapy: a call for innovative strategies. World J Urol Le Guevelou J, Anract J, Dariane C, Scheltema M, Bernardino R, Bianchi L, Kasivisvanathan V, Sibona M, Mari A, Sapoval M, Miszczyk M, Rajwa P, Boeken T, Marra G, YAU Prostate Group. PMID: 42059970 [PubMed - indexed for MEDLINE]
	PSMA PET: the answer to MRI-occult prostate cancerâ€¦ or another mirage? Eur Radiol Wagner T, Emberton M, Caglic I, Priftakis D, Giganti F, Kasivisvanathan V, Punwani S. PMID: 42059962 [PubMed - as supplied by publisher]
	Editorial Comment to Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. Int J Urol Kondo T. PMID: 42059774 [PubMed - in process]
	Vietnamese cohort study on non-renal cell carcinoma kidney cancers: Identifying tumor size as an independent prognostic factor. Urologia Thai KL, Nguyen DNT, Tran NQ, Dobbs RW, Choi SY, Nguyen TT, Ngo XT. PMID: 42059443 [PubMed - as supplied by publisher]
	Global trends and hotspots of machine learning in the diagnosis of prostate cancer: a bibliometric analysis from 1997 to 2024. Diagn Interv Radiol Shi Y. PMID: 42059442 [PubMed - as supplied by publisher]
	Integrated clinicopathological, genomic, and immunophenotypic landscape of renal tubulocystic oncocytoma. Front Immunol Wang W, Zhu H, Chen C, Sun M, Wang H, Tai Y, Chen S, Liu Z, Fan B, Li Y. PMID: 42058215 [PubMed - indexed for MEDLINE]
	An Integrated Graphene-MXene Electrochemical Transistor Array Platform for Accurate Prostate Cancer Diagnosis Using Plasma sEV-Derived E2F5 Biomarker. Small Mukherjee P, Sultana N, Sahu G, Goyal I, Besra L, Das P, Sarkar D, Bishnu D, Sharma P, Sengupta S, Chatterjee S, RoyChaudhuri C. PMID: 42057744 [PubMed - as supplied by publisher]
	Editorial Comment to Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database. Int J Urol Miyake M. PMID: 42057503 [PubMed - in process]
	Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. Int J Urol Miyazawa Y. PMID: 42057499 [PubMed - in process]
	Metabolic syndrome and risk of kidney cancer in the United States. Cancer Jung M, Wang X, Jeon SY, Graff RE, Deng Z, L'Espérance K, Li M, Langston ME, Chung BI. PMID: 42057471 [PubMed - indexed for MEDLINE]
	Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma. Discov Oncol Ling H, Wu G, Hu Y. PMID: 42056650 [PubMed]
	Quality and readability of online penile-cancer information: a Cross-Sectional Web Study. Int J Impot Res Ma J, Wang M, Liu Q, Chen Z, Li R, Huang Y, Zhang X. PMID: 42056491 [PubMed - as supplied by publisher]
	Oncological efficacy, functional outcomes and safety of MR-guided ultrasound ablation (MRgFUS/TULSA) for localized prostate cancer: a scoping review. Radiol Med Salvaggio G, Midiri F, Gagliardo C, Salerno S, Lupo G, Benfante V, Comelli A, Lo Re G, Galia M, Midiri M. PMID: 42056384 [PubMed - as supplied by publisher]
	Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study). Eur Urol Oncol Ploussard G, Coloby P, Chevallier T, Occéan BV, Kassab D, Houédé N, Villers A, Rischmann P. PMID: 42055879 [PubMed - as supplied by publisher]
	Quantifying the Heterogeneity of TRUS-Visible Lesions for Predicting Prostate Cancer: A Multicenter Preliminary Study. Acad Radiol Zheng B, Zhu J, Xu M, Wu X, Jiang J, Zhang Y, Shen C, Zhang Z, Huang H, Liu X. PMID: 42055868 [PubMed - as supplied by publisher]
	Transcriptome-based Deep Learning Model for Predicting Gemcitabine and Cisplatin Chemotherapy Response in Urothelial Carcinoma: Development and External Validation. Cancer Genomics Proteomics Kang J, Lee HJ, Oh SB, Nam JK, Kim TU, Ryu H, Ki YK, Kang J, Kim YR, Lee JH, Choi J, Hong YJ, Park K. PMID: 42055629 [PubMed - indexed for MEDLINE]
	Integrative multi-omics analysis identifies key ubiquitination regulators in prostate cancer. Transl Oncol Wei H, Gong C, Tan Z, Yang E, Huang Y, An Y, Li H, Lv D, Yang C, Chen W, Wang H, Li S, Ding M, Wang J. PMID: 42055487 [PubMed - as supplied by publisher]
	HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Natl Compr Canc Netw Vemula SSM, Kamal F, Fernet L, Afridi S, Shah N, Faheem MSB, Gergis S, Isaac D. PMID: 42055426 [PubMed - in process]
	Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study. JMIR Res Protoc Michalski K, Lorenzini T, Jedamzik T, Heinrich M, Kosmala A, Rauscher I, Bauch M, Reichl L, Amann L, Liebl S, Buck A, Eiber M, Lapa C, Claus R. PMID: 42054640 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 177871

Page 1 of 8894



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy